| Date Filed | Type | Description |
| 01/09/2012 |
PRN
| Inhibitex, Inc. Shareholder Alert: The Briscoe Law Firm and Powers Taylor, LLP Investigate the Board of Inhibitex, Inc. Concerning the Sale of INHX to Bristol-Myers Squibb |
| 06/01/2011 |
BW
| Inhibitex to Present at the Jefferies 2011 Global Healthcare Conference |
| 05/09/2011 |
BW
| Staphylococcus aureus Investigational Vaccine Elicits a Positive Immune Response in Phase 1 Study |
| 05/06/2011 |
BW
| Inhibitex Reports First Quarter 2011 Financial Results and Corporate Highlights |
| 04/27/2011 |
BW
| Inhibitex to Host Conference Call to Report First Quarter Financial Results on May 6, 2011 |
| 04/26/2011 |
BW
| Inhibitex to Present at Two Upcoming Investor Conferences |
| 04/12/2011 |
BW
| Inhibitex Announces Exercise of Underwriters' Overallotment Option and Closing of Underwritten Public Offering |
| 04/07/2011 |
PRN
| Inhibitex Prices $47 Million Public Offering |
| 04/06/2011 |
BW
| Inhibitex Announces Proposed Public Offering |
| 03/31/2011 |
BW
| Inhibitex Reports Positive Safety and Antiviral Data from Its Phase 1b Study of HCV Nucleotide Inhibitor INX-189 |
| 03/31/2011 |
BW
| Inhibitex Announces Data Presentation at the 46th Annual Meeting of the European Association for the Study of the Liver (EASL) |
| 03/11/2011 |
BW
| Inhibitex Reports Fourth Quarter and Calendar Year 2010 Financial Results and Corporate Highlights |
| 03/10/2011 |
BW
| Inhibitex to Present at the ROTH 23rd Annual Growth Stock Conference |
| 03/02/2011 |
BW
| Inhibitex to Present at the Cowen and Company 31st Annual Health Care Conference |
| 02/28/2011 |
BW
| Inhibitex to Host Conference Call to Report Fourth Quarter and Year-End 2010 Financial Results on March 11, 2011 |
| 02/11/2011 |
BW
| Inhibitex Receives Fast Track Designation for INX-189 for the Treatment of Chronic Hepatitis C Infections |
| 12/13/2010 |
BW
| Inhibitex to Present at the 2010 Deutsche Bank BioFEST Conference on Tuesday, December 14th |
| 12/13/2010 |
BW
| Inhibitex Reports Promising Top-Line Results from Phase II Trial of FV-100 for the Treatment of Shingles |
| 11/09/2010 |
BW
| Inhibitex Reports Third Quarter Financial Results and Corporate Highlights |
| 11/03/2010 |
BW
| Inhibitex Awarded $489,000 in Grants under the Therapeutic Discovery Tax Credit Program |
| 11/01/2010 |
BW
| Inhibitex Initiates Phase 1b Multiple Ascending Dose Trial of INX-189 in Patients with Chronic Hepatitis C |
| 10/29/2010 |
BW
| Inhibitex to Present at Two Upcoming Investor Conferences |
| 10/29/2010 |
BW
| Inhibitex to Host Conference Call to Report Third Quarter Financial Results on November 9, 2010 |
| 10/15/2010 |
BW
| Inhibitex Completes Enrollment in Phase II Clinical Trial of FV-100 in Shingles Patients |
| 09/13/2010 |
BW
| Inhibitex to Present at Three Upcoming Conferences |
| 08/10/2010 |
BW
| Inhibitex to Present at the Canaccord Genuity 30th Annual Growth Conference on Thursday, August 12th |
| 08/10/2010 |
BW
| Inhibitex Reports Second Quarter Financial Results and Corporate Highlights |
| 07/29/2010 |
BW
| Inhibitex to Host Conference Call to Report Second Quarter Financial Results on August 10, 2010 |
| 07/22/2010 |
BW
| Inhibitex Reports Independent Data Safety Monitoring Board Recommends Continuation of Phase II Clinical Trial of FV-100 |
| 06/28/2010 |
BW
| Inhibitex Added to Russell 3000® Index |
| 05/13/2010 |
BW
| Inhibitex Reports First Quarter Financial Results and Corporate Highlights |
| 04/30/2010 |
BW
| Inhibitex to Host Conference Call to Report First Quarter Financial Results on May 13, 2010 |
| 03/23/2010 |
BW
| Inhibitex Reports Fourth Quarter and Calendar Year 2009 Financial Results and Corporate Highlights |